Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

18.51 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 18.51
Bid (Size) 13.60 (1)
Ask (Size) 29.43 (1)
Prev. Close 18.51
Today's Range 18.51 - 18.51
52wk Range 13.82 - 24.21
Shares Outstanding 89,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
80% of people diagnosed with anxiety, depression report losing years or decades of time 
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire

Performance

YTD
-2.58%
-2.58%
1 Month
-14.31%
-14.31%
3 Month
-8.37%
-8.37%
6 Month
+26.26%
+26.26%
1 Year
-18.85%
-18.85%

More News

Read More
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics: Q4 Earnings Insights
Via Benzinga
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 27, 2024
Via Benzinga
Myriad Genetics Earnings Preview
Via Benzinga
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights
Via Benzinga
Evaluating Myriad Genetics: Insights From 4 Financial Analysts
Via Benzinga
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation
Via Benzinga
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
From Myriad Genetics, Inc.
Via GlobeNewswire
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.